| Evaluation of Various Static In Vitro–In Vivo Extrapolation Models for Risk Assessment of the CYP3A Inhibition Potential of an Investigational Drug MLT Vieira, B Kirby, I Ragueneau‐Majlessi, A Galetin, JYL Chien, ... Clinical Pharmacology & Therapeutics 95 (2), 189-198, 2014 | 104 | 2014 |
| Some considerations on the design of population pharmacokinetic studies S Duffull, T Waterhouse, J Eccleston Journal of pharmacokinetics and pharmacodynamics 32, 441-457, 2005 | 81 | 2005 |
| Optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics in cystic fibrosis patients TH Waterhouse, S Redmann, SB Duffull, JA Eccleston Journal of Pharmacokinetics and Pharmacodynamics 32, 521-545, 2005 | 58 | 2005 |
| A d‐optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients S Hennig, TH Waterhouse, SC Bell, M France, CE Wainwright, H Miller, ... British journal of clinical pharmacology 63 (4), 438-450, 2007 | 48 | 2007 |
| Design selection criteria for discrimination/estimation for nested models and a binomial response TH Waterhouse, DC Woods, JA Eccleston, SM Lewis Journal of Statistical Planning and Inference 138 (1), 132-144, 2008 | 39 | 2008 |
| Optimal design criteria for discrimination and estimation in nonlinear models TH Waterhouse, JA Eccleston, SB Duffull Journal of Biopharmaceutical Statistics 19 (2), 386-402, 2009 | 28 | 2009 |
| Optimal experimental design for nonlinear and generalised linear models TH Waterhouse | 24 | 2005 |
| Population pharmacokinetics and exposure–overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer I Gueorguieva, J Tabernero, D Melisi, T Macarulla, V Merz, ... Cancer chemotherapy and pharmacology 84, 1003-1015, 2019 | 21 | 2019 |
| The pharmacokinetics and pharmacokinetic/pharmacodynamic relationships of evacetrapib administered as monotherapy or in combination with statins S Friedrich, JJP Kastelein, D James, T Waterhouse, SE Nissen, ... CPT: pharmacometrics & systems pharmacology 3 (1), 1-9, 2014 | 17 | 2014 |
| On optimal design for discrimination and estimation TH Waterhouse, JA Eccleston, SB Duffull COMPSTAT 2004: Proceedings in Computational Statistics, 1963-1970, 2004 | 16 | 2004 |
| Development of a selective androgen receptor modulator for transdermal use in hypogonadal patients V Krishnan, NJ Patel, JG Mackrell, SA Sweetana, H Bullock, YL Ma, ... Andrology 6 (3), 455-464, 2018 | 14 | 2018 |
| Population pharmacokinetics of LY2623091 in patients with hypertension and chronic kidney disease EB Wang, A Chaudhary, TH Waterhouse, GL Dickinson The Journal of Clinical Pharmacology 57 (6), 739-746, 2017 | 13 | 2017 |
| Optimal crossover designs for logistic regression models in pharmacodynamics TH Waterhouse, JA Eccleston, SB Duffull Journal of Biopharmaceutical Statistics 16 (6), 881-894, 2006 | 9 | 2006 |
| Designs for generalized linear models with random block effects TW Waite, DC Woods, TH Waterhouse Southampton, GB, Southampton Statistical Sciences Research Institute, 23pp …, 2012 | 6 | 2012 |
| Bayesian estimation in NONMEM CK Johnston, T Waterhouse, M Wiens, J Mondick, J French, WR Gillespie CPT: Pharmacometrics & Systems Pharmacology 13 (2), 192-207, 2024 | 5 | 2024 |
| Design selection criteria for discrimination between nested models for binomial data TH Waterhouse, DC Woods, JA Eccleston, SM Lewis Southampton Statistical Sciences Research Institute, 2006 | 3 | 2006 |
| P206 Model-predicted lymphocyte response and recovery profiles for the sphingosine 1-phosphate receptor modulators ozanimod and etrasimod C Taylor, T Waterhouse, M Heathman, DA Oh, HK Komori, JS Grundy Gut 71 (Suppl 1), A140-A141, 2022 | 2 | 2022 |
| Exposure-response (overall survival [OS]) analyses of patients with unresectable pancreatic cancer (PC) treated with galunisertib+ gemcitabine (GG) or gemcitabine+ placebo (GP … I Gueorguieva, J Tabernero, D Melisi, TH Waterhouse, C Miles, ... Cancer Research 76 (14_Supplement), 2046-2046, 2016 | 1 | 2016 |
| A D-optimal designed population pharmacokinetic study of itraconazole capsules and solution in adults with cystic fibrosis S Hennig, TH Waterhouse, CE Wainwright, SC Bell, H Miller, BG Charles, ... Age (y) 26, 16-61, 2006 | 1 | 2006 |
| Population pharmacokinetic modeling of vedolizumab for graft‐versus‐host disease prophylaxis in adults with allogeneic hematopoietic stem cell transplant T Waterhouse, K Baron, W Eure, C Chen, NL Dirks, J Jansson, M Akbari, ... Pharmacology Research & Perspectives 12 (5), e1257, 2024 | | 2024 |
